<DOC>
	<DOCNO>NCT01926639</DOCNO>
	<brief_summary>Patients non-curable disseminated follicular lymphoma receive local radiotherapy target single lymph node injection low-dose rituximab ( anti-CD20 ) autologous dendritic cell . The therapy repeat 3 time , target different lesion . Aims induce tumor immunity clinical response .</brief_summary>
	<brief_title>Phase II Cancer Vaccine Trial Patients With Follicular Lymphoma</brief_title>
	<detailed_description>The clinical protocol base rationale immune system develop combat infectious disease . To mimic environment infect tissue , select tumor-affected lymph node treat locally single dose 8 Gy radiotherapy inject therapeutic antibody ( anti-CD20/Rituximab ) . Later , dendritic cell ( DC ) inject damage tumor tissue together stimulatory cytokine ( GM-CSF ) initiate immune response . Patients untreated relapsed stage III/IV follicular lymphoma need standard therapy receive intra-tumoral injection low-dose anti-CD20 antibody ( 5 mg ) day 1 3 local radiotherapy day 2 . On day 4 5 , dendritic cell generate monocyte isolate patient blood inject site together stimulatory cytokine GM-CSF administer subcutaneously . Additional lymph node treat similarly 2 4 week . The treatment thus perform three time , target different lymphoma node . The primary aim induce tumor-specific immune response clinical response .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Age 18 year old 2 . Histologically confirm ( WHO classification ) untreated relapsed indolent nonHodgkin 's Bcell lymphoma lowgrade follicular , marginal zone , lymphoplasmocytic small lymphocytic subtypes . 3 . Stage III/IV 4 . Adequate bone marrow function ( leukocyte count &gt; 2,0 , neutrophil count &gt; 1.0 , platelet &gt; 50 ) 5 . Two separate lymph node &gt; 1,5 cm available biopsy treatment . 6 . Measurable disease present biopsy site injection site ( ) . 7 . Required washout period previous treatment : Chemotherapy 8 week , Radiotherapy 4 week , Rituximab 12 week 8. WHO status 01 9 . Life expectancy 6 month 10 . Written inform consent 11 . Able comply treatment protocol 1 . Patients progressive lymphoma need systemic therapy standard dose irradiation . 2 . Chronic bacterial , viral fungal infection 3 . Preexisting autoimmune antibody mediate disease include : systemic lupus , erythematosus , rheumatoid arthritis , multiple sclerosis , Sjogren 's syndrome , autoimmune thrombocytopenia , exclude control thyroid disease , presence autoantibody without clinical autoimmune disease . 4 . Known history HIV 5 . Central nervous system involvement lymphoma 6 . Current anticoagulant therapy safely pause treatment injection ( ASA &lt; 325 mg/day allow ) 7 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Autologous dendritic cell</keyword>
	<keyword>Cancer vaccine</keyword>
</DOC>